ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart Failure
SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep a...
ResMed Wins Initial Decision in ITC Patent Infringement Action
SYDNEY and SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- An administrative law judge at the International Trade Commission (ITC) ruledFriday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC pr...
A New Beginning: ResMed's New Air Solutions Connected Care Platform for Treating Sleep-Disordered Breathing
SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today announced Air Solutions, a new forward-thinking connected care solution for treating sleep-disordered breathing that can benefit all stakeholders in the care continuum. The ResMed Air Solutions platform has data-driven components t...
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical...
ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
SAN DIEGO, July 21, 2014 /PRNewswire/ -- An International Trade Commission (ITC) ruling issued Friday held that, despite a redesign of its iCH CPAP device, Taiwanese device manufacturer APEX continues to infringe ResMed patents in its humidification. ResMed (NYSE: RMD) is the innovation leader an...
